Gilead Sciences: Lymphoma, Mantle-Cell trials
The registry lists 13 Lymphoma, Mantle-Cell studies with Gilead Sciences as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 4Phase 2 7Phase 3 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableNCT05776134
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)CompletedNCT04880434Phase 2Results posted
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedNCT02601313Phase 2Results posted
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01799889Phase 2Results posted
- Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01796470Phase 2Results posted
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT01088048Phase 1Results posted
- Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT06253663Phase 2
- Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesApproved for marketingNCT04162756
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid MalignanciesCompletedNCT01705847Phase 1
- Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedNCT00596804Phase 1/2
- Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaStatus unknownNCT00003338Phase 2/3
- Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00003337Phase 3